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Introduction
Percutaneous coronary intervention (PCI), a less invasive 
procedure than coronary artery bypass grafting (CABG), 
has been widely used for the treatment of coronary artery 
obstruction. The existing interventional medical devices 
are used in these procedures are associated with restenosis. 
To deal with restenosis drug eluting stents (DES) were 
introduced.
Introduction of DES primarily proven in-stent neointimal 
formation reduction and thereby minimized the occurrence 
of restenosis compare to bare-metal stents (BMS).
A lthough f irst-generat ion DES, Cypher (Cordis 
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Conclusions: The most significant experimental evidence appears to be earlier endothelialization at 7 days 
for SES which led to safety of the device. Efficacy of the device was also observed by a reduced neointimal 
thickness and minimized inflammatory score at all follow-ups. Termination of antiplatelet at 30 days has not 
shown any further complications. Polymer thickness was almost in negligible amount at 180 days with no 
inflammation.
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Corporation, J&J, NJ, USA) and Taxus (Boston Scientific 
Corporation, Natick, Mass, USA) were successfully 
achieved restenosis rate reduction. However, safety related 
issues of first generation DES; inf lammatory response, 
delayed healing causing late and very late thrombosis, and 
local drug toxicity were unanswered (1-9).
Both Cypher and Taxus were designed using durable 
polymers to carry and control the release of their 
antiproliferative agents. The permanent presence of these 
polymers has been correlated to local inflammatory responses 
and local toxicity in various preclinical analysis (10-13). 
Furthermore, durable polymers used in first-generation 
DES were associated with mechanical complications like 
polymer delamination and webbing which may create stent 
expansion issues (14) and non-uniform coating resulting 
in erratic drug distribution. Therefore safety issue remains 
unresolved in first generation DES. Second generation 
DES were focused on novel drug carrier systems including 
absorbable (or biodegradable) polymers and modified 
polymers (14-17).
Additional improvements includes, development of 
more modern platforms (e.g., better deliverability, radio-
opacity, flexibility, and radial strength) as well as the use of 
novel antiproliferative agents or reduced doses of current 
approved antiproliferative drugs.
Current approaches deliver the drug through entire 
stent surface i.e., inside and outside wall of the stent. 
Hypothetically any cytostatic or cytotoxic drug inhibits 
ECM building inside wall of the stent. Therefore DES with 
bio-degradable polymers and limited drug delivery through 
abluminal surface of the struts is gaining more and more 
importance (18-20).
The present in vitro and in vivo study has been designed 
to investigate the preclinical safety and efficacy of the 
Abluminus™ stent (SES). The stent contains sirolimus drug 
with mixture of biodegradable polymers coated on abluminal 
surface of stent and exposed surface of the balloon.
Materials and methods
PLLA, PLGA (50:50 lactide-co-glycolide) was obtained 
from Lakeshore Biomaterials and the rapamycin (sirolimus) 
was purchased from Biocon Ltd., India. The coated stents 
were prepared by spray-coating method as per reported 
method (21). In brief, 1% drug solution with polymers in 
dichloromethane was sprayed on the targeted stent surface 
and was allowed to dry for 10 minutes. Bare metal stent (BMS) 
was made of L605 alloy, were 16-20 mm in length and struts 
thickness of 73 µm which was also used as base platform of 
sirolimus eluting stent and polymer only coated stent.
Drug release profile of the stent samples were analysed 
by soaking in Hank’s solution. The samples were incubated 
at 37 ℃ with gentle rotation at 70 RPM. The elution 
volume was 2 mL and the entire volume was sampled and 
replenished at each time point. The elution curves were 
generated by measuring the amount of drug each stent, 
released into Hank’s solution by UV at 278 nm after 0, 1, 7, 
14, 30 and 60 days.
Device description
Abluminus™/Mitigator™/Nostrum™ (Envision Scientific 
Pvt. Ltd., India) is a pre-crimped stent coated with sirolimus 
on abluminal surface of the stent and balloon catheter. The 
novelty of the product was an abluminal coating of drug 
polymer matrix on the stent surface and exposed balloon 
surface in pre-crimped configuration. The schematic 
coating is shown in Figure 1.
Study design
The present study was performed as shown in Figure 2. In 
present investigation SES was used as test device, while two 
controls were BMS and polymer only coating on abluminal 
surface (PC).
The study was performed with the objective of 
demonstrating the effect of the SES on healing and 
neoint imal  prol i ferat ion by  us ing his to logy and 
histomorphometry. A total of 16 animals (n=40) were 
included in this study. The animals were divided into 
four groups, according to the follow-up time (7, 30, 90 or 
180 days). The two different control devices were 
compared with the SES stents. Endothelialization was 
evaluated at 7 days on SES and PC. For histology and 
histomorphometry, at 30-days, 13 stent were explanted 
(n=6 for SES, n=5 for BMS and n=2 for PC) and at 90 days 
20 stents were explanted (n=12 for SES, n=2 for BMS and 
n=6 for PC). PC (n=3) stents were explanted at 180 days for 
polymer degradation evaluation.
The coronary angiographies were carried out after each 
implant and at each follow-up. The angiograms confirmed 
patency of all the treated vessels. Thrombus presence, 
incomplete stent strut apposition and myocardial infarctions 
were not detected in any of implanted groups either by 
morphological heart examination or by histology.
Investigations was followed the CPCSEA (Committee 
256 Sojitra et al. Abluminal coated sirolimus eluting stent
© Cardiovascular Diagnosis and Therapy. All rights reserved. Cardiovasc Diagn Ther 2015;5(4):254-263www.thecdt.org
for the purpose of control and supervision of experiments 
on animals) Guidelines 1998 and the Guide for the Care 
and Use of Laboratory Animals, Indian National Science 
Academy, India, and those of the Italian Ministry of Health, 
Italy. The study protocol was approved by local ethical 
committee.
Safety and efficacy porcine study
Stent procedure description
Domestic young adult  piglets  (35 to 60 kg) were 
anesthetized and treated with antibiotics, then heparinised 
150 (IU/kg) by intra-arterial route (ACT >300 sec.). 
Surgical access was obtained through common carotid 
artery using 7 Fr introducer. A Judkins or Amplaz type 
guide catheter was introduced through the introducer 
by means of a 0.035 inch. The appropriate stent was 
delivered to the intended site over a guide wire with the 
use of fluoroscopic guidance, and stent deployment was 
performed using a 1:1.1 stent-to-artery diameter ratio. The 
devices were then expanded using appropriate pressures 
until they were well apposed to the vessel wall. Animals 
were recovered and housed until their designated day of 
euthanasia.
The antiplatelet treatment was limited to Aspirin® 
from two days before to the 30 day after the intervention 
and then suspended. No supplementary antiplatelet drugs 
(ticlopidine or clopidogrel) were administered.
At the end of the scheduled follow-up, each group of 
animals underwent a further angiographic examination 
in order to assess the vessel patency. The animals were 
anesthetised with intramuscular injections of 2 mg/kg di-
ketamine and 2 mg/kg of xylazine and by inhaling iso-
fluoran 1%. A 7 Fr introducer was positioned in the left 
carotid artery and a follow-up angiography was carried 
out on the implanted coronaries using a similar method to 
that described above. The animals received 14,000 IU of 
heparin intravenously administered. The animals were then 
euthanised by an intravenous injection of barbiturate 
(60 mg/kg) through the jugular access following the 
“AVMA guidelines on euthanasia (June 2007)”.
After the explant, the heart was submitted to X-ray 
A CB
Figure 1 Schematic cross section of pre-crimped coated stent (A) normal view (B) enlarged view (C) SEM image. SEM, scanning electron 
microscopy.
Figure 2 Schematic illustrating device distribution.
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analysis to confirm stent location. Hearts were excised and 
pressure perfused with a heparinised physiological solution 
until cleared of haematic traces. The stented arterial 
segments were then carefully dissected free from the heart.
The coronaries were fixed with a solution of formaldehyde 
at 4% at 150 mm/Hg pressure. Finally the coronary vessels 
were carefully dissected from epicardial surface preserving 
artery size and shape.
Histology protocol
Formalin post-fixed stent samples were analyzed for 
endothelialization by scanning electron microscopy (SEM). 
Stented segments for SEM were cut in longitudinally 
sections and were dried. Stereo microscope pictures were 
taken at high magnification before gold sputtering. At 30, 
90 and 180 day follow-up coronary arteries were dissected 
and stented coronary artery segments were processed for 
methyl-methacrylate embedding, while proximal and distal 
unstented vessel sections were paraffin embedded.
A representative number of 4 µm sections were cut 
perpendicularly to the long axis of the vessel by a precision 
microtome, at the proximal, mid and distal stent level 
and at proximal and distal unstented tracts. Histological 
sections were stained with haematoxylin and eosin (H&E) 
and Movat’s pentachromic stains to evidence elastic fibers; 
photomicrographs were taken for each segment of interest.
A vessel injury score was calculated according to the 
Schwartz method (22). Cross-sectional areas (external elastic 
lamina, internal elastic lamina, and lumen) of each section 
were measured with morphometry. Neointimal thickness 
was measured as the distance from the inner surface of 
each stent strut to the luminal border. Data were collected 
on each stent section and included strut apposition to the 
vessel wall, fibrin deposition around struts, granulomas, 
haemorrhage and giant cells around stent struts and were 
expressed as a percentage of the total number of struts in 
each section.
Histomorphometry
Endothelialization was calculated from the stereoscopic 
images measuring the non-coated strut surfaces over the 
total extent of strut surfaces. Neointimal thickness and 
neointimal area were measured on histological images, 
and percentage stenosis was consequently calculated. 
Patency was evaluated as percent of in-stent area stenosis, 
endothelialization percent and histomorphometric variables 
were analysed by Image-Pro Plus® software (Media 
Cybernetics Inc., Bethesda, MD, USA).
Polymer absorption study
Animals in PC group were additionally analysed for 
histomorphometric and histo-pathological measurements of 
residual polymer at 30, 90 and 180 days. Polymer thickness 
was measured at all struts included transverse section cut at 
defined time points. Minimum, maximum and mean values 
were reported for each evaluated stent.
Statistical analysis
The data are presented as mean ± SD for parametric 
data and frequency percentage for scores. Comparison 
among continuous variables were performed using one 
way ANOVA as data was normally distributed, adopting 
the Bonferroni t-test method for multiple comparison. 
Differences among inflammation scores were analysed with 
the Kruskal-Wallis test. Statistical analysis was performed 
using SAS 9.1.3 software (SAS Institute Inc., Cary, NC, 
USA). A P value of 0.05 or less was considered statistically 
significant.
Results
In vitro drug release
Small, medium and long size stent (n=9) were tested for in-
vitro drug release. The drug showed biphasic drug release; 
initially first 3-4 days burst release and then controlled 
release up to 48 days. Burst release was 40-50% in 3-4 days 
and rest 50% drug was released in 40-42 days (Figure 3). 
First order release kinetics was observed and drug release 
kinetics was similar in all length sizes.
In vivo drug loss
Whole blood was collected from the animals at each time 
interval (7, 30 and 90 days) for evaluation of drug content. 
The results did not show presence of sirolimus drug 
systemically.
Implant distribution
A total of 16 juvenile domestic pigs randomly received 
two or three stent implant in orthotopic position (at least 
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one stent in the left and one stent in the right coronary 
artery) using 40 investigational stents. The average implant 
pressure was 10.8 atm. Two pigs (n=2 for SES and n=2 
for PC) were sacrificed at seven days to conduct the SEM 
investigations and remaining animals were sacrificed at 
longer term follow-up. Thirteen stents were explanted at 
30 days and 20 stents were explanted at 90 days follow-
up for histological and histomorphometric examinations. 
The coronary angiographies carried out after implant and 
at each follow-up confirmed the patency of all treated 
vessels. Three stents were dissected at 180 days for 
histomorphometry.
Endothelialization at seven days
The specimens obtained from the stent longitudinal sections 
were observed by SEM in order to evaluate and measure the 
vessel healing in terms of quality and the percent extent of 
neo-endothelialization.
In Figure 4, the appearance at SEM examination of 
SES at seven days of implant is represented. Specimen 
surfaces SES, appears free from platelet aggregation and 
thrombotic clots. Morphometric assessment of the surface 
endothelialization was quantified in percent of strut 
coverage by a continuous carpet of endothelial cells. The 
results of these measurements indicate that endothelial cells 
covered uniformly almost 100% of the struts surface.
Histology evaluation
Histological evaluation for defined attributes was performed 
in all the three groups: SES, BMS and PC. The 30-day 
tissue response was in general minimal, with negligible 
infiltration of inflammatory cells (Figure 5). The neointimal 
surface was lined by a regular carpet of endothelium. 
Smooth muscle cells around the stent strut were also 
observed.
Neointimal growth was non-obstructive, characterised 
by an even distribution of a moderate number of cells in a 
proteoglycan matrix. Blood clots and minor fibrin deposits, 
mainly localised at strut proximity, were seen. The values 
were recorded at both the time points: 30 and 90 days. Cell 
populations [monocytes, polymorphonucleates (PMN) with 
smooth muscle cells the most numerous] and their density 
were assessed in proximal, mid and distal stent sections and 
showed no statistical differences between the two groups 
(Table 1).
The inflammation score was mild in general in all the 
stent groups, without statistical differences. Comparatively 
inflammation was higher in the PC stent group; also 
struts with granulomas were seen more remarkably in this 
group. SES and BMS are less stimulated the infiltration of 
monocytes, with a very low density, while, on the contrary 
their density was higher in the PC stent group at 30 and 
90 days.
At 90 days neointimal thickness maintained lower for 
the SES group (0.18±0.10 mm) as compared to the BMS 
(0.61±0.09 mm) and PC group (0.59±0.08 mm), (P<0.001). 
Neointimal area was also lower in the SES group as 
compared to the BMS and PC group (DES 1.1±0.55 mm2; 
BMS 1.92±0.36 mm2; PC 1.94±0.48 mm2; P<0.05). The 
percentage area stenosis was also maintained significantly 
lower in SES compared to the BMS and PC group (SES 
18%±11% vs. BMS 30%±12% vs. BMS + polymer only 
32%±14%, P<0.05). Also the medial area was higher in the 
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Figure 3 In vitro drug release.
Figure 4 SEM showing endothelialization at seven days. SEM, 
scanning electron microscopy.
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Figure 5 Histological section at low magnification marker on picture: (A) BMS at 30 days; (B) SES at 30 day; and (C) SES at 90 days. BMS, 
bare metal stent; SES, Abluminus™ stents.
BMS and PC group as compared to the SES group and 
were not statistically significant (BMS 2.82±0.81 mm2, PC 
group 2.98±0.69 mm2, SES 2.38±0.78 mm2; P= ns) (Figure 6).
Polymer absorption and thickness evaluation
At 180 days minimal and maximal polymer thickness, as 
well as mean polymer thickness were reduced as compared 
to 30 and 90 days.
Figure 7 shows that tissue response to polymer absorption 
in PC group at 180 days. No inflammatory response was 
observed at this time point. At 180 days residual minimal, 
maximal and mean polymer thickness was remarkably 
reduced (nearly complete absorbed) as shown in Figure 8A. 
Also inflammation response was absent at 180 days in PC 
group (Figure 8B). High magnification imaging was used to 
study and quantify in PC group.
Discussion
Endothelialization is critical step of vascular healing due to 
injury in vessel due to stent implantation. The origin of new 
endothelium may be from either the adjacent recruitment 
of endothelial cells (23). Circulating endothelial progenitor 
cells (EPC) have been shown to participate in repair of 
damaged or degenerating vascular surfaces (24,25).
Due to cytostatic or cytotoxic properties of certain 
drugs, a non-selective inhibition of all cells occurs in stent 
healing process (26-30). Non-selective inhibition results in 
alteration of vascular healing. Maintain sustained control of 
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Figure 6 Histomorphometric data plotted for 30 and 90 days comparing the three stent groups. (A) Medial area; (B) neointimal area; (C) % 
area stenosis; (D) neointimal thickness.
Table 1 Histology data (mean ± SD) comparison from implanted stent groups at 30 and 90 days
Attribute Device 30 days P value 90 days P value
Smooth muscle cells (cells/mm3) BMS 5,045±1,276 0.53 6,050±1,222 0.88
PC 5,559±701 6,208±1,145
SES 6.413±2.072 6,133±1,383
polymorphonucleates (cells/mm3) BMS 489±75 0.42 435±972 0.63
PC 512±60 645±234
SES 709±165 580±456
Monocytes (cells/mm3) BMS 276±146 0.67 960±480 0.67
PC 208±189 1,580±980
SES 312±247 1,323±790
Struts with inflammation (%) BMS 1.80±1.20 0.57 0.80±11.0 0.35
PC 7.80±6.60 10.6±14.0
SES 0.90±2.90 4.70±12.0
Struts with granuloma (%) BMS 3.40±2.7 0.42 0.00 0.54
PC 8.90±10.6 9.80±7.6
SES 2.30±2.4 0.70±0.9
BMS, bare metal stent; PC, polymer coated stents; SES, Abluminus™ stents.
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smooth cell proliferation in arterial wall without effecting 
extracellular matrix building process on luminal side is yet 
major challenge in present DESs (31-34). Selective drug 
elution from the stent surface is important and can be 
explained by abluminal coating on the stent and exposed 
surface of the balloon with control drug elution. Present 
sirolimus elution through abluminal surface of the stent and 
exposed surface of the balloon can reduces focal restenosis 
by more homogeneous drug delivery in artery and also 
take care of neointimal proliferation without hindrance 
of ECM building process on the luminal struts. This 
can demonstrate safety concerns related to the problems 
associated with first generation DES.
The study was mainly focused on safety and efficacy of 
abluminal coating sirolimus eluting stent formulated with 
absorbable polymers matrix. The SES showed early time 
100% endothelialization at 7 day compare to historical non-
polymeric DES (Cypher & Taxus) data (34).
Thrombus, incomplete stent strut apposition and 
myocardial infarctions were not detected in any of 
implanted groups e i ther  by morphological  heart 
examination or by histology. Injury scores were mild in all 
groups with decreasing pattern from 30 to 90 days. Fibrin 
was mildly present in few sections at 30 days in all three 
groups and was disappeared at 90 days.
Inflammation was minimal at 30 days in all three groups 
and was increased at 90 days in PC group which was absent 
at 180 days in same group. Mild inflammatory response 
increased at 90 days may be more likely due to polymer 
absorption, further bio-degradation of polymers in to 
their monomer acids like lactic or glycolic acid leads to 
acidic pH in local tissues. Decreasing inflammatory trend 
Figure 7 Histological sections at low (A) and high magnification (B) at 180 days in PC group. PC, polymer coated stents.
Figure 8 (A) Residual polymer in PC group stent at 30, 90 and 180 days; (B) granuloma (%) & intimal inflammation score. PC, polymer 
coated stents.
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in SES group shows effect of sirolimus over absorption of 
polymers. At 180 days, degraded acids might me degraded 
to carbon dioxide and water. Polymer end group of PLLA 
or PLGA may have produced less acid moieties and thereby 
it may have caused less inflammation.
Complete re-sorption of polymer at 180 days have near 
to null inflammation reaction which indicated marginal 
lower inflammatory response as compared the higher 
grade of inflammation in Cypher stent (12). Presence of 
granulomas compared to Cypher vs. SES vs. PC at 30 days 
was 14%, 2.30% and 8.9% while at 90 days it was 43%, 
0.70% and 9.8% respectively. At 180 days SES showed 
0% compare to 60% of Cypher (34). Permanent polymer 
placements of Cypher stent may have cause larger numbers 
of granuloma comparatively. No polymer residue at 180 days 
has resulted in lower granuloma %.
Significant reduction in neointima thickness (NIT) and 
percentage neointima hyperplasia (% NIH) was observed 
in SES group. Neointima thickness was 0.15 mm at 30 day 
follow-up, and remains 0.18 mm at 90 days, while BMS 
neointima was thicker 0.57 mm at 30 days and was 0.61 mm at 
90 days. Similarly, in the PC group, it was 0.52 to 0.59 mm 
respectively at 30 and 90 days. This difference in neointima 
thickness between SES and BMS/PC group was statistically 
significant (P<0.001). This shows that selective drug 
delivery from stent and balloon able to obstruct neointimal 
growth without affecting on endothelialization. It was 
further evidenced by endothelialization at 7 days.
After 30 days, the SES demonstrates intact internal 
elastic laminae, some mild fibrin deposits and limited 
haemorrhagic blood clots around few struts. At 180 days, 
inside the neointima, the healing process appears completed 
where all fibrin and haemorrhagic traces around the struts 
disappear without residual inflammation.
Conclusions
Abluminal coated SES, AbluminusTM, NostrumTM and 
MitigatorTM with biodegradable polymer is safe with no 
thrombus events, signs of delayed endothelialization and 
effective in reducing neointimal thickness. The results are 
yet to establish in human trials.
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